Thalassemia Market Size, Share & Trends Analysis Report By Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy), By Type (Alpha Thalassemia, Beta Thalassemia), By Region, And Segment Forecasts, 2024

Description

Thalassemia Market Growth & Trends:

The global thalassemia market size is expected to be valued at USD 1,430.1 million by 2030, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 7.8% from 2024 to 2030. Increase in demand for a universal cure, rise in awareness about the disease, and technological advancements are likely to increase the adoption of gene therapies.

Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in the destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in the U.S.

Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.

Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.

Thalassemia Market Report Highlights:

The iron chelating drugs segment held the largest revenue share of 52.7% in 2023. Patients with thalassemia often require regular blood transfusions, which can lead to iron overload in the body.
The beta thalassemia held the largest revenue share of 71.2% in 2023. Ongoing advancements in diagnostic techniques and treatment options for beta thalassemia have significantly improved patient outcomes.
North America thalassemia market dominated the global market with a revenue share of 42.8% in 2023.

Product Code: GVR-2-68038-349-2

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Thalassemia Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Thalassemia Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Thalassemia Market: Treatment Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Thalassemia Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
4.3. Iron Chelating Drugs
- 4.3.1. Iron Chelating Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Erythyroid Maturation Agents
- 4.4.1. Erythyroid Maturation Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Stem Cell therapy
- 4.5.1. Stem Cell Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Others
- 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Thalassemia Market: Type Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Thalassemia Market: Type Movement Analysis, 2023 & 2030 (USD Million)
5.3. Alpha Thalassemia
- 5.3.1. Alpha Thalassemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Beta Thalassemia
- 5.4.1. Beta Thalassemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Thalassemia Market: Regional Estimates & Trend Analysis

6.1. Thalassemia Market Share, By Region, 2023 & 2030 (USD Million)
6.2. North America
- 6.2.1. North America Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.2. U.S.
  - 6.2.2.1. U.S. Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.3. Canada
  - 6.2.3.1. Canada Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.4. Mexico
  - 6.2.4.1. Mexico Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Europe
- 6.3.1. Europe Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. UK.
  - 6.3.2.1. UK Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Germany
  - 6.3.3.1. Germany Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.4. France
  - 6.3.4.1. France Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.5. Italy
  - 6.3.5.1. Italy Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.6. Spain
  - 6.3.6.1. Spain Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.7. Denmark
  - 6.3.7.1. Denmark Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.8. Sweden
  - 6.3.8.1. Sweden Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.9. Norway
  - 6.3.9.1. Norway Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
- 6.4.1. Asia Pacific Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.2. Japan
  - 6.4.2.1. Japan Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.3. China
  - 6.4.3.1. China Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.4. India
  - 6.4.4.1. India Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.5. Australia
  - 6.4.5.1. Australia Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.6. South Korea
  - 6.4.6.1. South Korea Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.7. Thailand
  - 6.4.7.1. Thailand Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
- 6.5.1. Latin America Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. Brazil
  - 6.5.2.1. Brazil Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Argentina
  - 6.5.3.1. Argentina Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Middle East and Africa
- 6.6.1. Middle East and Africa Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. South Africa
  - 6.6.2.1. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. Saudi Arabia
  - 6.6.3.1. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.4. UAE
  - 6.6.4.1. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.5. Kuwait
  - 6.6.5.1. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
- 7.4.1. CHIESI Farmaceutici S.p.A.
  - 7.4.1.1. Participant's Overview
  - 7.4.1.2. Financial Performance
  - 7.4.1.3. Product Benchmarking
  - 7.4.1.4. Recent Developments/ Strategic Initiatives
- 7.4.2. Bristol-Myers Squibb Company
  - 7.4.2.1. Participant's Overview
  - 7.4.2.2. Financial Performance
  - 7.4.2.3. Product Benchmarking
  - 7.4.2.4. Recent Developments/ Strategic Initiatives
- 7.4.3. Sun Pharmaceutical Industries Ltd.
  - 7.4.3.1. Participant's Overview
  - 7.4.3.2. Financial Performance
  - 7.4.3.3. Product Benchmarking
  - 7.4.3.4. Recent Developments/ Strategic Initiatives
- 7.4.4. Cipla
  - 7.4.4.1. Participant's Overview
  - 7.4.4.2. Financial Performance
  - 7.4.4.3. Product Benchmarking
  - 7.4.4.4. Recent Developments/ Strategic Initiatives
- 7.4.5. Fresenius Kabi AG
  - 7.4.5.1. Participant's Overview
  - 7.4.5.2. Financial Performance
  - 7.4.5.3. Product Benchmarking
  - 7.4.5.4. Recent Developments/ Strategic Initiatives
- 7.4.6. Novartis Pharmaceuticals Corporation
  - 7.4.6.1. Participant's Overview
  - 7.4.6.2. Financial Performance
  - 7.4.6.3. Product Benchmarking
  - 7.4.6.4. Recent Developments/ Strategic Initiatives
- 7.4.7. Apotex Inc.
  - 7.4.7.1. Participant's Overview
  - 7.4.7.2. Financial Performance
  - 7.4.7.3. Product Benchmarking
  - 7.4.7.4. Recent Developments/ Strategic Initiatives
- 7.4.8. bluebird bio, Inc.
  - 7.4.8.1. Participant's Overview
  - 7.4.8.2. Financial Performance
  - 7.4.8.3. Product Benchmarking
  - 7.4.8.4. Recent Developments/ Strategic Initiatives

Thalassemia Market Size, Share & Trends Analysis Report By Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy), By Type (Alpha Thalassemia, Beta Thalassemia), By Region, And Segment Forecasts, 2024 - 2030